-Both 12-month pivotal studies in patients with symptomatic Chronic
Obstructive Pulmonary Disease (COPD) meet primary endpoints
-Data shows reductions in moderate and severe exacerbations requiring medical intervention
-Application for marketing authorisation in EU and US expected for 2009
-Partnering process for commercialisation in the US will be initiated
Nycomed today announced encouraging results from a preliminary analysis of four Phase III trials of Daxas® (roflumilast) in the treatment of symptomatic COPD......
- New network structure for improved competitiveness
- European production from five centres of competence and five regional supply facilities to ensure high customer service level
- Nycomed in Denmark will focus on regional and local supply
- Negotiations to sell Finnish manufacturing facility
Nycomed today announced a new strategy for its European manufacturing network......
Strong sales in key home markets
Core products continue to develop very well
Veltuzumab in-licensing significantly strengthens pipeline
Oncology sale successfully closed
The financial results reported in this press release are related to Nycomed S......
Preclinical anti-cancer program sold to Bayer Schering Pharma
Bayer Schering Pharma will assume full development and commercialization rights
Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program......
Licensing agreement with Immunomedics
Worldwide rights for veltuzumab in non-oncology indications and subcutaneous application
First subcutaneous anti-CD20 tested in clinical trials
Significant enhancement to Nycomed’s autoimmune and inflammation pipeline
Nycomed and Immunomedics today announced a collaboration and licensing agreement on Immunomedics’ veltuzumab......
Strategic decision to divest oncology projects
Eight anti-cancer projects in preclinical stage and clinical phase I
Martinsried based 4SC will assume full development and commercialization rights
Nycomed today agreed with 4SC on the sale of a major part of Nycomed’s R&D projects in the field of oncology......
Very satisfactory first quarter, despite lower sales
Adjusted EBITDA increases due to lower costs
Most home markets performed very well
Major advancements in US out-licensing strategy
Bradley Pharmaceuticals integration largely finalised
Agreement with Zydus Cadila to shift API production to Indian joint venture
The financial results reported in this press release are related to Nycomed S......
New leadership for Commercial Operations
Nycomed today announced the appointment of Guido Oelkers as the new Executive Vice President Commercial Operations. It is planned that he joins Nycomed in September 2008......
Joint venture contract with Zydus Cadila to be amended for the production of active pharmaceutical ingredients (API)
Transfer of chemical production from facilities in Singen (Germany) and Linz (Austria) to India until 2011
Singen and Linz will focus on pharmaceutical production
Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India......
Total net turnover increases by 3.0% to € 3,497.4 million
31.0% increase in adjusted EBITDA
Instanyl™ filed for European approval
Own Pantoprazole generic as response to US at-risk launch
Major progress in US out-licensing strategy
Acquisition of Bradley Pharmaceuticals successfully closed
The financial results reported in this press release are related to Nycomed S......
Nycomed creates a leading specialty pharmaceutical player in dermatology
Enhanced platform for in-licensing and co-promotion of dermatology products
Combined US dermatology sales of $450 million
Today, Nycomed successfully completed the acquisition of Bradley Pharmaceuticals, a company focused on niche therapeutic markets in the United States......
Legal counsel to be integral part of Executive Committee
Nycomed’s Board of Directors has appointed Michael Kuner Executive Vice President Legal. He joins the company’s Executive Committee with immediate effect......
-Own presence in Venezuela to further enhance strong Latin American presence
-Nycomed strategy to participate in high-growth markets and offer licensing opportunities to partners
Nycomed is about to establish its own marketing and sales organisation in Venezuela......
Own generic of Pantoprazole introduced to US market
Move in response to at-risk launch of generic Pantoprazole in the United States
Nycomed and Wyeth remain convinced of valididity and enforcability of their patent and continue to pursue litigation
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the U......
Sepracor acquires exclusive development, marketing and commercialisation rights to the Ciclesonide franchise in the United States
Ciclesonide is the active ingredient in the ALVESCO® Inhalation Aerosol for asthma and the Omnaris™ Nasal Spray for allergic rhinitis
ALVESCO® and Omnaris™ are FDA-approved and are on track to be launched in 2008
Agreement is in alignment with Nycomed’s strategy to cooperate with the best partners for its key brands in the United States
Partnership between Nycomed and Sepracor provides a good strategic fit for both companies
Nycomed has granted Sepracor, Inc......
ALVESCO® (ciclesonide) Inhalation Aerosol approved by FDA for the maintenance and prophylactic treatment of asthma in patients 12 years of age and older
ALVESCO® will be commercialised by U......
Surgical patch TachoSil® planned to enter US market with partner Baxter
Important milestone for Nycomed’s partnership strategy for the US market
Nycomed grants Baxter International Inc......
Marketing authorisation application filed for Europe through the Centralised Procedure
Treatment aimed at opioid tolerant patients with cancer experiencing breakthrough pain
Strengthening the Nycomed pain control portfolio
Nycomed filed a marketing authorisation application with the European Medicines Agency (EMEA) for an intranasal fentanyl spray in Europe on December 7, 2007......
Net turnover increases by 4.9% for the first nine months of 2007
29.4% increase in adjusted EBITDA
Strong margin growth and reduced spending
Integration of Altana Pharma ahead of plan with
positive effect on business opportunities and spending levels
Bid for Bradley Pharmaceuticals
Teduglutide in-licensed
The financial results reported in this press release are related to Nycomed S......
Acquisition will add to the branded dermatologic line as a growth driver for the future
Integration of Bradley will provide an enhanced platform for in-licensing and co-promotion of dermatology products
Bradley Pharmaceuticals will be integrated with the PharmaDerm and Fougera divisions of Nycomed’s US specialty business
Combined sales of Nycomed US and Bradley amount to approximately €320 million/$450 million on an annualised basis
Nycomed today announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc......
Nycomed acquires exclusive rights outside North America
GATTEX™ matches Nycomed’s capabilities in gastroenterology
Total upfront payments of $35 million and potential for more than $150 million milestone payments
Nycomed and NPS Pharmaceuticals, Inc......
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey denied Nycomed’s and Wyeth’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc......
The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprises all of the Nycomed Group’s operations including the ALTANA Pharma activities acquired in December 2006......
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey has taken the matter of Wyeth and Nycomed’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc......
Nycomed and its partner NPS Pharmaceuticals announced today that they have entered an agreement expanding and amending rights and responsibilities under the Preotact® (full-length parathyroid hormone [PTH 1-84]) license originally entered into in 2004......
Today Nycomed announced that its partner Neurim Pharmaceuticals EEC, the EU subsidiary of Neurim Pharmaceuticals Ltd has received a European Marketing Authorisation for Circadin® 2 mg (prolonged release melatonin)......
Nycomed has moved into new corporate headquarters in Zurich and the Company’s headquarters function is now officially transferred from Denmark to Switzerland.
The new headquarters will be base for the majority of Nycomed’s central function heads and core teams, such as CEO, Integration, Commercial Operations, Legal, Human Resources, Business Development, Communications and Finance/Procurement......
Nycomed’s investigational surfactant product Venticute® (rSP-C- Surfactant) has been granted “Fast Track” designation by the United States Food and Drug Administration for reduction of mortality in patients with severe acute pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation and severe oxygenation impairment......
The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprises all of the Nycomed Group’s operations including the ALTANA Pharma activities acquired in December 2006......
Nycomed and Micromet Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoim-mune Diseases......
Nycomed will take back the Alvesco® product rights from sanofi-aventis, the co-development and marketing partner for the US market. The collaboration with sanofi-aventis for the development and commercialization of the combination product of ciclesonide with formoterol in the US continues......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Major bleeding in patients treated for Acute Coronary Syndromes (ACS) nearly triples the risk of death at one year.
One-year findings from the landmark ACUITY trial show that acute coronary syndrome (ACS) patients in the “Angiox® (bivalirudin) alone” treatment group had similar rates of ischemic clinical outcomes compared with more complicated standard therapy, confirming previous findings, which showed similar ischemia at 30 days, and nearly 50% fewer episodes of major bleeding......
Today Nycomed provided information about the framework for the group integration following the acquisition of ALTANA Pharma AG. With the planned restructuring measures, Nycomed adjusts to a changing market and prepares for the future......
Today Nycomed announced the official launch of the combined group following the acquisition of ALTANA Pharma AG which was completed on 31 December 2006. Nycomed will now focus on integrating the two companies, while ensuring that the high level of customer service is maintained......
Nycomed and ALTANA AG have announced the closing of the transaction from the New Year transferring ALTANA Pharma AG to Nycomed.
At a closing ceremony in Frankfurt today, the formal transfer of shares from ALTANA AG to Nycomed was signed by representatives of both sides......
Today, the shareholders of ALTANA AG approved the sale of ALTANA Pharma to Nycomed at an Extraordinary General Meeting.
On 21 September 2006, Nycomed announced that it had reached an agreement to acquire ALTANA Pharma AG, the pharmaceutical business of German-based international pharmaceuticals and chemicals group, ALTANA AG, for a total value of € 4......
Nycomed today announced that it has received the necessary merger approvals from competition authorities in the EU and the US, allowing the Company, in coordination with ALTANA AG, to continue the transaction process according to plan......
Anders Ullman has been appointed to lead Nycomed’s research and development function upon approval and completion of the deal to purchase ALTANA Pharma.
Anders Ullman has a 16 year track record of medical research and development, most recently as Senior Vice President, Research & Development, at the European biopharma company Biovitrum......
Nycomed and DURECT Corporation (Nasdaq: DRRX), a US-based emerging specialty pharmaceutical company, today announced the signing of a license agreement for POSIDUR™ (SABER™-bupivacaine), a long-acting and local pain relief depot for the treatment of post-surgical pain, currently in Phase II clinical development
As part of the agreement, Nycomed and DURECT will establish and co-fund a joint development program designed to bring POSIDUR through Phase III clinical development, and aim to achieve European and US regulatory approval of POSIDUR......
Nycomed today announced an offer to purchase and consent solicitation for any and all of its 11.50% Senior Notes due 2013 and any and all of its 11.75% PIK Notes due 2013......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Plans for Nycomed’s proposed purchase of ALTANA Pharma AG moved forward today with the announcement of the Executive Committee that will lead the new company upon approval and completion of the deal......
Nycomed today commences the syndication of its new € 5.7 billion senior credit facilities, the proceeds of which will be used to finance its previously announced acquisition of ALTANA Pharma and to refinance existing debt......
Today Nycomed announced that it has reached an agreement to acquire ALTANA Pharma AG, the pharmaceutical business of German-based international pharmaceuticals and chemicals group, ALTANA AG......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Today, Nycomed announced the acquisition of Romanian pharmaceutical company, Ruby De Tacos, thereby further strengthening its European presence.
With a population of 22......
Clinical trial of Nycomed’s pipeline product AI-700, an ultrasound contrast agent for use in the evaluation of coronary artery disease, showed positive preliminary results......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
The European Commission has approved and issued EU marketing authorisation for Nycomed’s new osteoporosis product, Preotact.
Nycomed and its US collaborator NPS Pharmaceuticals Inc......
Nycomed announced today that the Swedish health authorities have approved ZyComb, the first combination nasal spray for the simultaneous treatment of the two major symptoms of the common cold – nasal congestion and runny nose......
Nycomed and its US collaborator, The Medicines Company, announced today the first 30 days results from the global 13,819 patient ACUITY trial. The trial data were presented today at the annual American College of Cardiology scientific session in Atlanta, USA......
The responsibilities of Nycomed’s leadership team has been revised to place greater emphasis on sales and marketing.
Effective from May 2006:
Kerstin Valinder is appointed Senior Vice President Business Development and International Sales with responsibility for both business strategy, in-licensing and out-licensing (international sales and exports)......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
The European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending EU marketing authorisation for Preotact®.
Nycomed and its US collaborator NPS Pharmaceuticals Inc (Nasdaq: NPSP) have successfully reached a milestone in the European registration process of Preotact®......
The European Committee for Medicinal Products for Human Use (CHMP) recommends extension of TachoSil® indication.
Nycomed announced today that CHMP, the scientific committee of the European Medicines Agency (EMEA), has adopted a positive opinion, recommending an extension of indication for TachoSil® , Nycomed’s surgical patch for bleeding control......
Importance of Russia-CIS market and focus on European growth reflected in Nycomed top management addition
Nycomed announced today that Jostein Davidsen (46), Managing Director of its Russia-CIS business, has been appointed to the company’s Executive Management team......
Nycomed contributes with more than 4,200 European patients leading to completion of ACUITY, a global landmark trial within acute coronary syndromes.
Nycomed and its US collaborator, The Medicines Company, announced today the completion of patient enrolment in the 13,800 patient global phase III ACUITY trial......
The official opening of Nycomed’s office in Spain took place today, a move that is a major milestone in the growth of this European healthcare company
Today, Nycomed announced that it has officially opened its office in Madrid, Spain......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Nycomed announced today that Dick Söderberg (47) has been appointed Senior Vice President, International Sales.
Dick Söderberg will be responsible for the strategic and operational management of the International Sales department based in Nycomed’s corporate headquarters in Denmark......
The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
The financial results reported in this release are related to the fully-owned Nycomed subsidiary, Nyco Holdings 2 ApS, which through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Nycomed and its US collaborator NPS Pharmaceuticals Inc (Nasdaq: NPSP) have received confirmation from the European Medicines Agency (EMEA) that assessment of the market authorisation application (MAA) for Preotact™ in Europe has now begun......
The European Society of Cardiology (ESC), a leading independent cardiology body in Europe, this week published its ‘Guidelines for Percutaneous Coronary Interventions’, which recommended that bivalirudin replaces heparins in patients undergoing percutaneous coronary interventions (PCI)......
The financial results reported here are for the parent company, Nyco Holdings A/S. The full annual report is available at www.nycomed.com | investors | company reports.
Interim financial information for the fully-owned subsidiary, Nyco Holdings 2 ApS is available at www......
Nycomed and ZLB Behring today announced the signing of a ten-year market and distribution agreement for Beriplast® P Combi-Set, a wound healing product manufactured by ZLB Behring......
The financial results reported in this release are related to the fully-owned Nycomed subsidiary, Nyco Holdings 2 ApS, which through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Nycomed has launched Angiox™ (bivalirudin), first in a new generation of anticoagulants approved for Europe. From today, Angiox™ is available in Austria, Denmark, Finland, Germany and Sweden, and will be launched throughout Europe in the coming months......
Nycomed has, together with its US collaborator The Medicines Company (Nasdaq: MDCO), successfully achieved EU marketing authorisation for a new cardiovascular product, Angiox™ (bivalirudin), which will be marketed by Nycomed......
Clinical trial data has confirmed the efficacy and safety of ZyComb™, a new combination nasal spray for the simultaneous treatment of the two major symptoms of common cold – nasal congestion and runny nose......
Nycomed announced today, 7 July 2004, that it has entered into a collaboration, license and supply agreement with Acusphere Inc (NASDAQ: ACUS) granting Nycomed the rights to develop and market Acusphere's lead product candidate, AI-700, in Europe, including the Commonwealth of Independent States (CIS) and Turkey......
Nycomed has together with its US collaborator, The Medicines Company (Nasdaq:MDCO), successfully reached a milestone in the European registration process of Angiox™ (bivalirudin)......
The European Commission has issued an EU marketing authorisation (MA) for Nycomed’s new surgical product TachoSil™. This decision follows the Agency for the Evaluation of Medicinal Products’ (EMEA) announcement on 27 February of a positive scientific assessment for TachoSil™......
The financial results reported in this release are related to the fully-owned Nycomed subsidiary, Nyco Holdings 2 ApS, which through its subsidiaries and affiliates comprises all of the Nycomed Group’s operations......
Salt Lake City, Utah and Roskilde, Denmark, 21. April 2004, NPS Pharmaceuticals Inc (Nasdaq: NPSP) and Nycomed Group today announced that they have signed a distribution and license agreement granting Nycomed rights to develop and market the investigational osteoporosis drug PREOS® in Europe, including the Commonwealth of Independent States (CIS) and Turkey......
Nycomed has successfully reached a milestone in the European registration process of TachoSil™. As part of the Centralised Procedure under the European Agency for the Evaluation of Medicinal Products (EMEA), the scientific assessment report is now available to Nycomed......
Nycomed has established sales offices in Oxford, UK, thereby entering the UK market for pharmaceutical products.
The UK is the third largest pharmaceutial market in Europe, with 14......
Nycomed announced today, 11 December 2003, an agreement to sell its non-pharmacy consumer health business to the Norwegian private equity company Ferd.
The deal includes the sale of Nycomed’s Norwegian consumer health business, Collett Pharma AS and the retail-chain sales in Denmark, Finland and Sweden......
Nycomed establishes sales offices in Milan, Italy, thereby entering the Italian market for pharmaceutical products. The Italian office will be operational from 1 November 2003......
Nycomed announced today, 18 September 2003, that its non-pharmacy business (Consumer Division) in Norway will be moved into a separate and newly established company, Collett Pharma AS, which will be fully owned by Nycomed......
Nycomed announced today, 18 September 2003, that the six-month results of the REPLACE-2 clinical trial conducted by Nycomed’s collaborator, The Medicines Company, confirmed the findings of the 30-day analysis, further supporting the transition from heparin to bivalirudin (Angiomax® in the US) as the foundation anticoagulant in coronary angioplasty and stenting......
Nycomed announced today, 11 September 2003, that Alejandra Mørk has been appointed Senior Vice President, International Product Development (IPD).
Alejandra Mørk takes over the position from Thor-Björn Conradson, who built up Nycomed’s IPD department following his appointment in 1999......
Highlights
Second quarter net turnover increased by €14.6 million, or 10.2%
Half year net turnover increased by €28.4 million, or 9.8%
Acquired remaining 49% stake in Oy Leiras Finland Ab
Established affiliate offices in the UK and Italy
Successfully in-licensed Almogran® and MT100 for the Nordic region
Angiomax (bivalirudin) product development running on schedule
Completed Tachosil (tissue sealant) clinical trials
Financial performance
We achieved a net turnover of €157......
Nycomed Group announced today that the Market Authorisation Application (MAA) filed by its collaborator The Medicines Company has been submitted to the European Agency for the Evaluation of Medicinal Products (EMEA) for the use of bivalirudin (Angiomax® in the U......
Chapel Hill, N.C. and Roskilde, Denmark, July 1, 2003—POZEN Inc. (NASDAQ: POZN), and Nycomed announced today that they have signed a licensing agreement for the commercialization of MT 100 in four Nordic countries......
Nycomed announced today that Mr Ulf Strinnholm has been appointed as Senior Vice President for Marketing & Sales Scandinavia. Mr Strinnholm, whom up till now has been head of Pharmaceuticals in Nycomed Scandinavia, will continue in his position as Managing Director of Nycomed Sweden......
The Nycomed Group and Almirall, announced today that their co-operation has been extended to include the marketing rights of Almogran® (almotriptan) by Nycomed Group in the Nordic region......
Highlights
During the first quarter 2003, Nycomed achieved a net turnover of €161.1 million, representing an increase of 9.3% over the same period in 2002.
On 31 December 2002, Nycomed purchased an additional 26......
The Schering Group and Nycomed Group have agreed that Nycomed will acquire from Schering the remaining 49% of Oy Leiras Finland Ab's shares. Closing of the transaction is May 31, 2003......
Nycomed has invested more than € 18 million in the enlargement and modernisation of the company’s calcium plant in Asker, Norway. The factory, which is inaugurated today, is the world’s biggest tablet production site for pharmaceutical calcium......
On November 29, 2002, a consortium of investors led by CSFB Private Equity and Blackstone Capital Partners acquired 100% of the issued share capital of Nycomed Holding ApS, through a newly established holding company, Nyco Holdings ApS......
Nycomed has appointed Mr Timo Tiivola as Senior Vice President for Marketing & Sales to drive development in Finland, Russia / CIS and the Baltic States. He joins from Pfizer LTD, where he was Chairman & Managing Director of the UK and Ireland......
Late Friday 29 November, the agreement for the purchase of Nycomed Holding A/S, the European healthcare company, was formally closed. This follows the EU Commission’s approval of Nycomed’s acquistion from Nordic Capital by a consortium of investors led by CSFB Private Equity, and including Blackstone Capital Partners and NIB Capital Private Equity NV......
A late-breaking presentation at the American Heart Association's Scientific Sessions 2002 has demonstrated that all primary and secondary objectives for the landmark REPLACE-2 clinical trial of Angiomax® (bivalirudin) have been met......
Nordic Capital has entered into a definitive agreement to sell Nycomed, the European market-driven pharmaceutical company, to a company owned by CSFB Private Equity, Blackstone Capital Partners and NIB Capital Private Equity NV......
On April 9, at a press conference held at Nycomed's new facilities in Moscow, the management of the company announced its serious intention of being among the top five leading international pharmaceutical companies in Russia in a few years......
Nycomed has entered into a collaboration with The Medicines Company under which Nycomed will be the exclusive distributor of ANGIOMAX® (bivalirudin) in 23 European countries, and also in Russia/CIS......
Merck KGaA has selected Nycomed Pharma of Denmark as its distribution partner for pharmaceuticals in Russia and the Community of Independent States (CIS).
Nycomed was one of the pioneers among the pharmaceutical companies in Russia/CIS after the fall of the Soviet Union......
Leiras Oy (subsidiary of Schering AG) and Nycomed Holding A/S have agreed to establish a jointly owned company in Finland to be named Oy Leiras Finland Ab. The company will consist of Nycomed Pharma's Finnish business, Oy Nycomed Ab, and the domestic business of Leiras Oy......